S&CO Inc. Has $297,000 Stake in Baxter International Inc (BAX)

S&CO Inc. lowered its position in Baxter International Inc (NYSE:BAX) by 20.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,855 shares of the medical instruments supplier’s stock after selling 1,000 shares during the period. S&CO Inc.’s holdings in Baxter International were worth $297,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of BAX. Bridgeworth LLC purchased a new position in shares of Baxter International in the 2nd quarter worth approximately $102,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Baxter International by 3,088.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,435 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 1,390 shares during the last quarter. Baker Ellis Asset Management LLC purchased a new position in shares of Baxter International in the 2nd quarter worth approximately $111,000. Centaurus Financial Inc. purchased a new position in shares of Baxter International in the 2nd quarter worth approximately $117,000. Finally, Whittier Trust Co. of Nevada Inc. grew its position in shares of Baxter International by 84.4% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 1,748 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 800 shares during the last quarter. 82.28% of the stock is currently owned by hedge funds and other institutional investors.

BAX stock opened at $63.66 on Thursday. The company has a market capitalization of $33.75 billion, a P/E ratio of 25.67, a P/E/G ratio of 1.71 and a beta of 1.02. The company has a quick ratio of 2.00, a current ratio of 2.60 and a debt-to-equity ratio of 0.38. Baxter International Inc has a 52 week low of $61.05 and a 52 week high of $78.38.



Baxter International (NYSE:BAX) last released its earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.06. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.79 billion. Baxter International had a net margin of 10.90% and a return on equity of 17.67%. Baxter International’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period last year, the business earned $0.64 EPS. As a group, equities research analysts forecast that Baxter International Inc will post 3 EPS for the current fiscal year.

In other Baxter International news, SVP Giuseppe Accogli sold 17,647 shares of Baxter International stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $77.27, for a total transaction of $1,363,583.69. Following the completion of the sale, the senior vice president now directly owns 59,452 shares in the company, valued at approximately $4,593,856.04. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.05% of the stock is owned by company insiders.

A number of research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Thursday, November 1st. JPMorgan Chase & Co. lifted their price objective on shares of Baxter International from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 27th. Citigroup lifted their price objective on shares of Baxter International from $74.00 to $76.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. Morgan Stanley lifted their price objective on shares of Baxter International from $68.00 to $75.00 and gave the stock an “underweight” rating in a research report on Thursday, October 11th. Finally, Zacks Investment Research downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 24th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $75.25.

WARNING: This article was reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://dakotafinancialnews.com/2018/11/08/sco-inc-has-297000-stake-in-baxter-international-inc-bax.html.

Baxter International Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: Growth Stocks, What They Are, What They Are Not

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply